Skip to Content

Opicapone Approval Status

FDA Approved: No
Generic name: opicapone
Company: Neurocrine Biosciences, Inc.

Opicapone is a selective catechol-O-methyltransferase (COMT) inhibitor in development as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes.

Development Status and FDA Approval Process for opicapone

DateArticle
Jul 10, 2019Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease
Feb 14, 2018Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data
Feb  9, 2017Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide